

Curriculum vitae

Date Prepared: September 3, 2019

Name: Kevin Dale Courtney

Office Address: 6000 Harry Hines Blvd. NB2.102K
Dallas, TX 75390

Work Phone: 214-648-4180

Work E-Mail: kevin.courtney@utsouthwestern.edu

Work Fax: 214-648-1955

Place of Birth: Keene, New Hampshire

Education

Year	Degree (Honors)	Field of Study (Thesis advisor for PhDs)	Institution
1993	B.A., <i>summa cum laude</i>	Major: Chemistry	Dartmouth College, Hanover, NH
2001	Ph.D.	Molecular Cancer Biology Thesis Advisor: Ann Marie Pendergast, Ph.D.	Duke University, Durham, NC
2002	M.D.	Medicine	Duke University School of Medicine, Durham, NC
2016	M.S.C.S.	Master of Science in Clinical Sciences	University of Texas Southwestern Medical Center Graduate School of Biomedical Sciences

Postdoctoral Training

Year(s)	Titles	Specialty/Discipline (Lab PI for postdoc research)	Institution
6/02-6/03	Intern	Internal Medicine	University of California, San Francisco (UCSF)
7/03-6/04	Junior Resident	Internal Medicine	UCSF
7/04-6/05	Senior Resident	Internal Medicine	UCSF
7/05-6/08	Clinical Fellow in Medicine	Hematology/Oncology	Dana-Farber/Partners Cancer Care (Dana-Farber Cancer Institute, Brigham & Women's Hospital, and Massachusetts General Hospital) Boston, MA

7/06-12/11	Post-Doctoral Fellow	Laboratory PI: Lewis Cantley, Ph.D.	Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA
------------	----------------------	-------------------------------------	---

Faculty Academic Appointments

Year(s)	Academic Title	Department	Academic Institution
2008-2011	Instructor in Medicine	Medicine, Division of Hematology / Oncology	Harvard Medical School , Boston, MA
2012-2019	Assistant Professor	Medicine, Division of Hematology / Oncology	UT Southwestern Medical Center, Dallas, TX
2019-	Associate Professor	Medicine, Division of Hematology / Oncology	UT Southwestern Medical Center, Dallas, TX

Current Licensure and Certification

Licensure

2003-2005	California Medical Licensure
2005-2012	Commonwealth of Massachusetts Medical Licensure
2012-	Texas Medical Licensure

Board and Other Certification

2005-2015	Board Certification in Internal Medicine
2008-	Board Certification in Medical Oncology (certification renewed in 2018 through 2028)

Honors and Awards

Year	Name of Honor/Award	Awarding Organization
1991	Francis L. Town Scientific Prize in Chemistry	Dartmouth College
1992	Phi Beta Kappa	Phi Beta Kappa Society
1993	Chandler T. White 1916 Research Prize	Dartmouth College
1993	Sigma Xi	Sigma Xi Scientific Honor Society
1993	Presidential Scholar	Dartmouth College
1993-2002	Medical Scientist Training Program Traineeship	Duke University and National Institutes of Health
1998-2000	Breast Cancer Research Program Pre-doctoral Traineeship Award	Department of Defense
2008	Young Investigator Award	American Society of Clinical Oncology (ASCO)
2008	Kidney Cancer Career	Genentech, Inc. Dana-Farber/Partners Cancer Center

	Development Award	
2013	Clinical Research Scholar	UT Southwestern Department of Clinical Sciences
2015	Golden Pager Award	UT Southwestern University Hospitals Nursing Staff
2016	Friends of the Comprehensive Cancer Center 2016 Award in Cancer Research	UT Southwestern Medical Center and the Friends of the Comprehensive Cancer Center
2017	Wheels for Wellness Classic Hero Award of Gratitude	Wheels for Wellness Foundation and Moncrief Cancer Institute
2019	John W. Boddie, Ph.D. & Joan Reisch, Ph.D. Fund in Prostate Cancer Research in Honor of Dr. Kevin Courtney	UT Southwestern Medical Center through an endowment from Joan Reisch, Ph.D.

Appointments at Hospitals/Affiliated Institutions

<u>Past</u>			
Year(s)	Position Title	Department/Division	Institution
07/08-12/11	Attending Physician	Medicine / Medical Oncology	Dana-Farber Cancer Institute, Boston, MA
07/08-12/11	Attending Physician	Medicine / Medical Oncology	Brigham & Women's Hospital, Boston, MA
2012-2015	Attending Physician	Medicine / Hematology / Oncology	UT Southwestern St. Paul University Hospital

<u>Current</u>			
Year(s)	Position Title	Department/Division	Institution
2012-	Attending Physician	Medicine / Hem/Onc	UT Southwestern Medical Center
2012-	Attending Physician	Medicine / Hem/Onc	Zale Lipshy University Hospital
2012-	Attending Physician	Medicine / Hem/Onc	Parkland Health & Hospital System
2015-	Attending Physician	Medicine / Hem/Onc	UT Southwestern Clements University Hospital

Major Administrative/Leadership Positions

Year(s)	Position Title	Institution
2012-	Co-Leader, Genitourinary Oncology Disease Oriented Team	UT Southwestern Harold C. Simmons Comprehensive Cancer Center

Committee Service (*Member, unless noted otherwise*)

Year(s)	Name of Committee	Institution/Organization
---------	-------------------	--------------------------

<u>UTSW</u>		
2012-	Protocol Review Monitoring Committee	UT Southwestern Harold C. Simmons Comprehensive Cancer Center
2017-	ACS Institutional Research Grant Review Committee	UT Southwestern Harold C. Simmons Comprehensive Cancer Center
2017-	Friends of Comprehensive Cancer Center Review Committee	UT Southwestern Harold C. Simmons Comprehensive Cancer Center

<u>National/International</u>		
2012-	GU Committee	Eastern Cooperative Oncology Group / American College of Radiology Imaging Network (ECOG/ACRIN) Cancer Research Group
2017-	Via Oncology – Via Pathways Committees for Prostate Cancer, Bladder & Kidney Cancer, and Testicular Cancer	Via Oncology

Professional Societies

Dates	Society Name, member
2007-2008	American Society of Clinical Oncology, Associate Member
2008-present	American Society of Clinical Oncology, Full Member
2009-2016	American Association for Cancer Research, Member
	Committees
	Fellowships

Grant Review Activities

Year(s)	Name of Review Committee	Organization
2017	Friends of Comprehensive Cancer Center Review Committee	UT Southwestern Harold C. Simmons Comprehensive Cancer Center
2017	ACS Institutional Research Grant Review Committee	UT Southwestern Harold C. Simmons Comprehensive Cancer Center
2017	Mitacs Accelerate Research Internship	Mitacs Accelerate
2018	Kidney Cancer Research Program (KCRP)	Kidney Cancer Research Program

	Concept Award Cell Biology – Pathobiology (CON-CB-PB)	(KCRP) Department of Defense Congressionally Directed Medical Research Programs (DOD CDMRP)
2018	2018 Developmental Funds for Basic Science Pilot Projects	UT Southwestern Harold C. Simmons Comprehensive Cancer Center
2018	Kidney Cancer SPORE CEP/ DRP	UT Southwestern Kidney Cancer Program and Harold C. Simmons Comprehensive Cancer Center
2018	ACS Institutional Research Grant Review Committee	UT Southwestern Harold C. Simmons Comprehensive Cancer Center
2019	Mitacs Accelerate Research Internship	Mitacs Accelerate

Editorial Activities

Year(s)	Journal Name
<u>Editor/Associate Editor</u>	
None	

<u>Editorial Board</u>	
None	

<u>Ad Hoc Reviewer</u>	
2012	Front Endocrinol (Lausanne)
2014	Nature Communications
2014	Journal of Urology
2016	International Journal of Radiation Oncology, Biology, Physics
2017	Drugs of Today
2017	BMC Cancer
2018	Journal of Clinical Oncology
2018	Clinical Genitourinary Cancer

Invited Lectures

Year(s)	Title	Location
<u>International</u>		

<u>National</u>		
2013	Medical Learning Institute Live CME Meeting Series, entitled “2013 Comprehensive Cancer Network: Integration of Novel Management Strategies for Castrate-Resistant Prostate Cancer”	Texas Tech University Health Sciences Center, Lubbock, TX
2014	1 st Annual Summit on Practical and Emerging Trends in Prostate Cancer	Four Seasons Resort and Club, Irving, TX

<u>Regional/Local</u>		
2012	Prostate Cancer Working Group Meeting	UT Southwestern Medical Center
2013	Urology Grand Rounds	UT Southwestern Medical Center
2013	UT Southwestern Advanced Imaging Research Center Symposium	Belo Mansion & Pavilion, Dallas, TX
2014	Update in Internal Medicine – UT Southwestern Medical Center – “Prostate Cancer”	UT Southwestern Medical Center
2014	UTSW Guest Lecturer - "The Advances in Systemic Treatment of Prostate Cancer" – for radiation oncology residents’ conference	UT Southwestern Medical Center
2014	UTSW Internal Medicine Grand Rounds	UT Southwestern Medical Center
2015	21 st Annual Paul C. Peters Urology Symposium – “Bone Health in Urology Patients: Treatment and Prevention”	UT Southwestern Medical Center
2015	UTSW-CTSA-SCCC Small Molecule Drug Development Symposium – “Response Criteria”	UT Southwestern Medical Center
2015	Hamon Center for Therapeutic Oncology Research Conference – “Clinical and translational research in prostate and kidney cancer”	UT Southwestern Medical Center
2016	UTSW Bladder Cancer Survivorship Support Group – “Systemic therapy for bladder cancer”	UT Southwestern Medical Center
2016	Texas Urological Society 2016 Annual Meeting – “Advanced Prostate Cancer Therapies”	The Fairmont, Dallas, TX
2016	UT Southwestern Medical Center CME – “Cancer Genetics: Finding Meaning in Tumor and Germline Genomes”	UT Southwestern Medical Center
2017	Presbyterian Hospital – Plano Prostate Cancer Support Group: “Management of rising PSA (biochemical recurrence) after local therapy for prostate cancer”	Presbyterian Hospital, Plano, TX
2017	UTSW Urology Residents Lecture: “Advanced Prostate Cancer Therapies”	UT Southwestern Medical Center
2017	North Texas Prostate Cancer Coalition Prostate Cancer Symposium 2017: “Advanced Prostate	Globe Life Park, Arlington, TX

	Cancer Therapies”	
2017	UTSW Internal Medicine Residents Lecture: “Prostate Cancer and Testicular Cancer”	UT Southwestern Medical Center
2017	UTSW Radiation Oncology Residents Lecture: “Advanced Prostate Cancer Therapies”	UT Southwestern Medical Center
2017	UTSW Nuclear Medicine Residents Lecture: “Prostate Cancer for the Nuclear Medicine Physician – An Oncologist’s Perspective”	UT Southwestern Medical Center
2018	63 rd Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging Southwestern Chapter: “Clinical Perspective on Prostate Cancer”	Frisco Convention Center, Frisco, TX
2018	Update in Internal Medicine – UT Southwestern Medical Center: “Prostate Cancer”	UT Southwestern Medical Center
2018	Hamon Center for Therapeutic Oncology Research Conference – “ <i>In Vivo</i> Metabolic Studies of Kidney Cancer”	UT Southwestern Medical Center
2018	UTSW Simmons Cancer Center Cancer Cell Networks Retreat - “ <i>In Vivo</i> Metabolic Studies of Kidney Cancer”	UT Southwestern Medical Center
2019	25 th Annual Paul C. Peters Urology Symposium – “Genetic Testing for Prostate Cancer”	Four Seasons Resort and Club Dallas At Las Colinas, Irving TX
2019	Dallas Internists’ Club – “Prostate Cancer”	UT Southwestern Medical Center

Service to the Community

Year(s)	Role	Organization or institution
2017-	Medical advisor to the North Texas Prostate Cancer Coalition (NTxPCC). The NTxPCC is a volunteer organization of prostate cancer patients and family members. The mission statement of the NTxPCC is, “To inform the Texas community by providing coordinated educational support about prostate cancer for all men and their families, and to be a collective voice in elevating prostate cancer to major health priority status in the State of Texas through increased awareness and advocacy.” I serve as one of their medical advisors.	North Texas Prostate Cancer Coalition (NTxPCC)

Grant Support

<u>Present</u>	
2014-	Astellas Scientific and Medical Affairs, Inc.
	PI – Investigator initiated clinical trial (see trial listed in separate Clinical Trials section)

	below)
	\$124,224.50
	Phase II study of enzalutamide (MDV3100) and gonadotropin-releasing hormone (GnRH) agonist before, during and after radiation therapy in treatment of patients with high-risk localized prostate cancer
Goal	To evaluate the safety, tolerability, efficacy, and potential associated biomarkers of treatment with enzalutamide combined with GnRH therapy and radiation therapy in subjects with high-risk localized and locally advanced prostate cancer
2014-	Young Texans Against Cancer Grant
	PI
	\$35,000 (materials and supplies)
	Metabolic profiling of prostate cancer in vivo to identify potential novel therapeutic targets
Goal	To study metabolism in tumors from patients with prostate cancer
2016-	Friends of the UTSW Simmons Comprehensive Cancer Center
	PI
	\$50,000
	Pilot clinical trial of 11C-acetate-PET/CT vs [18F]FDG-PET/CT imaging in patients with metastatic clear cell renal cell carcinoma receiving standard of care systemic therapy (see trial listed in separate Clinical Trials section below)
Goal	To test the feasibility of 11C-acetate PET/CT imaging to identify clear cell renal cell carcinoma metastases and assess their response to therapy
2016-	Specialized Program of Research Excellence (SPORE) Award for Kidney Cancer (PI: James Brugarolas, MD, PhD)
	Co-Leader, Project 1; Co-Investigator, Project 3
	\$11 Million total funding for the SPORE

<u>Past</u>	
2008-2009	ASCO
	Young Investigator Award
	PI
	\$47,500
	Identification of activators of phosphoinositide 3-kinase signaling in renal cell carcinoma as potential therapeutic targets
Goal	The goal of this project is to identify novel therapeutic targets in the treatment of kidney cancer.
2008-2010	Genentech DF/HCC
	Career Development Award
	PI

	\$103,306
	Evaluation of phosphoinositide 3-kinase (PI3K) and CXCR4 activation in renal cell carcinoma
Goal	Renal cell carcinoma (RCC) is a leading cause of cancer death. Metastatic RCC responds poorly to conventional chemotherapy or immunomodulatory therapy. However, small molecule inhibitors of kinases implicated in the pathogenesis of RCC are more effective therapeutic agents in the treatment of kidney cancer. The goal of the proposed project is to improve our ability to predict responsiveness to existing inhibitors and to identify novel therapeutic targets by defining the signaling pathways that promote RCC proliferation and metastasis.
2013-2015	NIH/NCATS KL2TR001103 (UT Southwestern Center for Translational Medicine, Robert Toto MD - PI)
	Clinical Research Scholar
	\$51,000
	Major goal: To provide the crucial infrastructure necessary for medical scientists to discover and apply new diagnostics and therapeutics for the detection, diagnosis, treatment and prevention of disease, and thereby achieve the goal of improving our nation's health in a safe, ethical and responsible manner that ensures the individual's well-being and the public's trust.
2013-2015	American Cancer Society Institutional Research Grant
	New Investigator Award in Cancer Research – ACS-IRG-02-196
	PI
	\$40,000
	Metabolic profiling of kidney and prostate cancer to identify potential novel therapeutic targets
Goal	To study metabolism in tumors from patients with prostate cancer or kidney cancer

Grant Support: Clinical Trials

	NOTE: Only studies for which I have served as the PI or UTSW site PI are listed
<u>Present</u>	<i>Grantor:</i> NCI Eastern Cooperative Oncology Group (ECOG)
	<i>Title of Project:</i> ECOG 2809: Phase II, Randomized Study of MK-2206 – Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy (NCT01251861)
	<i>Role:</i> Site PI for UT Southwestern
	<i>Grantor:</i> Astellas Scientific and Medical Affairs, Inc.
	<i>Title of Project:</i> Phase II study of enzalutamide (MDV3100) and gonadotropin-releasing hormone (GnRH) agonist before, during and after radiation therapy in treatment of patients with high-risk localized prostate cancer
	<i>Role:</i> PI – investigator-initiated clinical trial
	<i>Grantor:</i> NCI Alliance for Clinical Trials in Oncology
	<i>Title of Project:</i> A031201: PHASE III TRIAL OF ENZALUTAMIDE (NSC # 766085) VERSUS ENZALUTAMIDE, ABIRATERONE AND PREDNISONE

	FOR CASTRATION RESISTANT METASTATIC PROSTATE CANCER
	<i>Role:</i> Site PI for UT Southwestern
	<i>Grantor:</i> Corvus Pharmaceuticals, Inc.
	<i>Title of Project:</i> A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers
	<i>Role:</i> Site PI for UT Southwestern
	<i>Grantor:</i> Peloton Therapeutics, Inc.
	<i>Title of Project:</i> A Phase 1, Multiple-dose, dose-escalation Trial of PT2385 Tablets, A Hif-2 α Inhibitor, in Patients with Advanced Clear Cell Renal Cell Carcinoma
	<i>Role:</i> Site PI for UT Southwestern
	<i>Grantor:</i> Astellas Pharma Global Development, Inc (APGD)
	<i>Title of Project:</i> A Multinational, Phase 3, Randomized, Double-blind, Placebo controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
	<i>Role:</i> Site PI for UT Southwestern
	<i>Grantor:</i> Stemline Therapeutics, Inc.
	<i>Title of Project:</i> A Phase 1 Trial of SL-801, a Novel Inhibitor of XPO1 Nuclear Export, in Patients With Advanced Solid Tumors
	<i>Role:</i> Site PI for UT Southwestern
	<i>Grantor:</i> UT Southwestern Simmons Comprehensive Cancer Center and UT Southwestern Kidney Cancer Program
	<i>Title of Project:</i> Multiparametric MR imaging as a pharmacodynamic marker in a phase 1, multiple-dose, dose-escalation trial of PT2385, a HIF-2 α inhibitor alone (Part 1) or in combination with nivolumab (Part 2) in patients with advanced clear cell renal cell carcinoma
	<i>Role:</i> PI – investigator-initiated clinical trial
	<i>Grantor:</i> Eli Lilly and Company
	<i>Title of Project:</i> A Double-Blind, Placebo-Controlled, Randomized, Phase II Study of Enzalutamide with or without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer
	<i>Role:</i> Site PI for UT Southwestern
	<i>Grantor:</i> Clovis Oncology, Inc.
	<i>Title of Project:</i> A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency
	<i>Role:</i> Site PI for UT Southwestern
	<i>Grantor:</i> Peloton Therapeutics, Inc.
	<i>Title of Project:</i> An Open Label Phase 2 Study to Evaluate PT2977 for the Treatment of

	von Hippel-Lindau Disease-Associated Renal Cell Carcinoma
	<i>Role:</i> Site PI for UT Southwestern
	<i>Grantor:</i> Stemline
	<i>Title of Project:</i> A Phase 1 Study of SL-801, a Reversible Inhibitor of Nuclear Export, in Patients with Advanced Solid Tumors
	<i>Role:</i> Site PI for UT Southwestern
	<i>Grantor:</i> PrECOG, LLC.
	<i>Title of Project:</i> Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
	<i>Role:</i> Site PI for UT Southwestern
<u>Pending</u>	<i>Grantor:</i> UT Southwestern Harold C. Simmons Cancer Center Friends of the Comprehensive Cancer Center
	<i>Title of Project:</i> [11C]Acetate PET in patients with Clear Cell Renal Cell Carcinoma metastases before and after treatment to test the feasibility of using [11C]Acetate PET imaging to assess treatment response (A non-therapeutic observational imaging protocol)
	<i>Role:</i> PI – Investigator initiated clinical trial (pending regulatory approval)
	<i>Grantor:</i> Exelixis
	<i>Title of Project:</i> A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors
	<i>Role:</i> Site PI for UT Southwestern (pending final regulatory approval)
<u>Past</u>	<i>Grantor:</i> NCI - Southwest Oncology Group (SWOG)
	<i>Title of Project:</i> S1216: A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer
	<i>Role:</i> Site PI for UT Southwestern
	<i>Grantor:</i> Hoffman – La Roche
	<i>Title of Project:</i> A Phase III. Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib plus Abiraterone plus Prednisone/Prednisolone in Adult Male Patients with Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer
	<i>Role:</i> Site PI for UT Southwestern
	<i>Grantor:</i> Merck Sharp & Dohme Corp.
	<i>Title of Project:</i> Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Chemotherapy (KEYNOTE-199)
	<i>Role:</i> Site PI for UT Southwestern
	<i>Grantor:</i> Progenics Pharmaceuticals, Inc.
	<i>Title of Project:</i> A Phase 2, Open-Label Multicenter Study of PSMA ADC in Subjects

	with Metastatic Castration Resistant Prostate Cancer (mCRPC)
	<i>Role:</i> Site PI for UT Southwestern
	<i>Grantor:</i> Astellas Pharma Europe B.V.
	<i>Title of Project:</i> A Multicenter, Single-Arm, Open Label Treatment Protocol to Provide Expanded Access to MDV3100 and Monitor Its safety in Patients with Progressive Castration-Resistant Prostate Cancer Previously Treated with Docetaxel-Based Chemotherapy
	<i>Role:</i> Site PI for UT Southwestern
	<i>Grantor:</i> Pfizer
	<i>Title of Project:</i> A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer (PREVAIL) (NCT01212991)
	<i>Role:</i> Site PI for UT Southwestern
	<i>Grantor:</i> Aragon Pharmaceuticals, Inc.
	<i>Title of Project:</i> A Multicenter, randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer
	<i>Role:</i> Site PI for UT Southwestern

Teaching Activities

<u>Postgraduate medical education (graduate & continuing medical education)</u>	
<u>Lectures</u>	
2012	Hematology/Oncology Fellows lecture: Prostate Cancer
2013	Hematology/Oncology Fellows lecture: Prostate Cancer
2013	Hematology/Oncology CMC lecture: Updates on castration resistant prostate cancer
2013	UTSW Urology Grand Rounds
2014	Hematology/Oncology Fellows lecture: Prostate Cancer
2014	Hematology/Oncology CMC lecture: “Can patients with high-risk and locally-advanced prostate cancer benefit from treatment with the androgen signaling inhibitor enzalutamide combined with a GnRH agonist and external beam radiation therapy (EBRT)?”
2014	UT Southwestern Update in Internal Medicine: “Prostate Cancer”
2014	UTSW Radiation Oncology Residents Teaching Conference: "The Advances in Systemic Treatment of Prostate Cancer"
2014	Internal Medicine Grand Rounds: ”Metastatic prostate cancer: current and emerging therapies”
2015	Hematology/Oncology Fellows lecture: Prostate Cancer
2016	Hematology/Oncology Fellows lecture: Prostate Cancer
2016	Hematology/Oncology CMC lecture
2016	Texas Urological Society 2016 Annual Meeting: “Advanced Prostate Cancer Therapies”
2016	UT Southwestern Medical Center Cancer Genetics CME – “Cancer Genetics: Finding

	Meaning in Tumor and Germline Genomes”
2016	UTSW Urology Residents Lecture: “Advanced Prostate Cancer Therapies”
2017	UTSW Internal Medicine Residents Lecture: “Prostate Cancer and Testicular Cancer”
2017	UTSW Radiation Oncology Residents Lecture: “Advanced Prostate Cancer Therapies”
2017	UTSW Nuclear Medicine Residents Lecture: “Prostate Cancer for the Nuclear Medicine Physician – An Oncologist’s Perspective”
2018	Hematology / Oncology CMC: Early Prostate Cancer
2018	Hematology / Oncology CMC: Advanced Prostate Cancer
2018	Hematology / Oncology Fellows Case Discussion: Prostate Cancer
2018	Update in Internal Medicine – UT Southwestern Medical Center: “Prostate Cancer”
2019	Hematology / Oncology CMC: Non-Metastatic Prostate Cancer
2019	Hematology / Oncology CMC: Metastatic Prostate Cancer
<u>Inpatient Teaching</u>	
2013-2017	Solid Tumor Oncology Inpatient Teaching Service UT Southwestern Medical Center St. Paul University Hospital (2013-2015), Clements University Hospital (2016-2017)
<u>Outpatient Clinic Teaching</u>	
2012-2018	Faculty supervisor, Hematology/Oncology Fellows Manual: Genitourinary Oncology chapter section: “Prostate Cancer”
2013-2018	Supervision of medical oncology and urologic oncology fellows in clinic
2013-2018	Supervision of internal medicine residents in Cancer Center oncology clinic
<u>Graduate Student Teaching and Mentoring</u>	
2014	UTSW Mechanisms of Disease & Translational Science Graduate Track Clinical Research Immersion summer rotation - graduate student mentor (Krishna Luitel; thesis research mentor Dr. Jerry Shay)
2017	UTSW Mechanisms of Disease Bedside to Bench Independent Study – graduate student mentor (Divya Bezwada; thesis research mentor Dr. Ralph DeBerardinis)
2017-	Mentoring – Divya Bezwada, PhD candidate (DeBerardinis lab) Project: <i>In Vivo</i> Metabolic Studies of Kidney Cancer
2018 -	Mentoring – Jake Lichterman, DO, UTSW Internal Medicine Resident, PSTP Projects: (1) [11C]Acetate PET in patients with Clear Cell Renal Cell Carcinoma metastases before and after treatment to test the feasibility of using [11C]Acetate PET imaging to assess treatment response (2) Review article of HIF inhibition in the treatment of renal cell carcinoma
2019	UTSW Mechanisms of Disease & Translational Science Graduate Track Clinical Research Immersion summer rotation - graduate student mentor (Sean Dilliard; thesis research mentor Dr. Daniel Siegwart)

Bibliography

Peer-Reviewed Publications

Original Research Articles

1.	Stearns DM, Courtney KD , Giangrande PH, Pheiffer LS, and Wetterhahn KE Chromium (VI) reduction by ascorbate: role of reactive intermediates in DNA damage in vitro. <i>Environmental Health Perspectives</i> 1994; 102 (Suppl 3): 21-5.
2.	Stearns DM, Kennedy LJ, Courtney KD , Giangrande PH, Pheiffer LS, and Wetterhahn KE. Reduction of chromium (VI) by ascorbate leads to chromium-DNA binding and DNA strand breaks in vitro. <i>Biochemistry</i> 1995; 34: 910-9.
3.	Dai Z, Quackenbush RC, Courtney KD , Grove M, Cortez D, Reuther GW, and Pendergast AM. Oncogenic Abl and Src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a Ras-independent pathway. <i>Genes and Development</i> 1998; 12: 1415-24.
4.	Quackenbush RC, Reuther GW, Miller JP, Courtney KD , Pear WS, and Pendergast AM. Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr-Abl tyrosine kinases. <i>Blood</i> 2000; 95: 2913-21.
5.	Courtney KD , Grove M, Vandongen H, Vandongen A, LaMantia A-S, and Pendergast AM. Localization and phosphorylation of Abl-interactor proteins, Abi-1 and Abi-2, in the developing nervous system. <i>Molecular and Cellular Neuroscience</i> 2000; 16: 244-57
6.	Stradal T,* Courtney KD ,* Rottner K, Hahne P, Small JV, and Pendergast AM. The Abl interactor proteins localize to sites of actin polymerization at the tips of lamellipodia and filopodia. <i>Current Biology</i> 2001; 11: 891-5. * These authors contributed equally to this work.
7.	Nakabayashi M, Werner L, Courtney KD , Buckle G, Oh WK, Bublely GJ, Hayes JH, Weckstein D, Elfiky A, Sims DM, Kantoff PW, Taplin ME. Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer (CRPC). <i>BJU International</i> 2012; 110:1729-35.
8.	Anastasiou D, Yu Y, Israelsen WJ, Jiang JK, Boxer MB, Hong BS, Tempel W, Dimov S, Shen M, Jha A, Yang H, Mattaini KR, Metallo CM, Fiske BP, Courtney KD , Malstrom S, Khan TM, Kung C, Skoumbourdis AP, Veith H, Southall N, Walsh MJ, Brimacombe KR, Leister W, Lunt SY, Johnson ZR, Yen KE, Kunii K, Davidson SM, Christofk HR, Austin CP, Inglese J, Harris MH, Asara JM, Stephanopoulos G, Salituro FG, Jin S, Dang L, Auld DS, Park HW, Cantley LC, Thomas CJ, Vander Heiden MG. Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. <i>Nature Chemical Biology</i> 2012; 8:839-47.
9.	Emerling BM, Benes CH, Poulogiannis G, Bell EL, Courtney K , Liu H, Choo-Wing R, Bellinger G, Tsukazawa KS, Brown V, Signoretti S, Soltoff SP, and Cantley LC. Identification of CDCP1 as a hypoxia-inducible factor 2 α (HIF-2 α) target gene that is associated with survival in clear cell renal cell carcinoma patients. <i>PNAS</i> 2013; 110:3483-3488.
10.	Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B; PREVAIL Investigators . Enzalutamide in metastatic prostate cancer before chemotherapy. <i>NEJM</i> 2014; 371:424-433.
11.	Courtney KD , Manola JB, Elfiky AA, Ross R, Oh WK, Yap JT, Van den Abbeele AD, Ryan, CW, Beer TM, Loda M, Priolo C, Kantoff P, and Taplin ME. A phase I study of everolimus and docetaxel in patients with castration resistant prostate cancer. <i>Clinical Genitourinary Cancer</i> 2015; 13:113-123.
12.	Krabbe LM, Westerman ME, Margulis V, Raj GV, Sagalowsky AI, Courtney K , Arriaga Y, Lotan Y. Changing trends in utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer. <i>Can J Urol</i> 2015; 22:7865-7875.
13.	Chen W, Hill H, Christie A, Kim MS, Holloman E, Pavia-Jimenez A, Homayoun F, Ma Y,

	Patel N, Yell P, Hao G, Yousuf Q, Joyce A, Pedrosa I, Geiger H, Zhang H, Chang J, Gardner KH, Bruick RK, Reeves C, Hwang TH, Courtney K , Frenkel E, Sun X, Zojwalla N, Wong T, Rizzi JP, Wallace EM, Josey JA, Xie Y, Xie XJ, Kapur P, McKay RM, Brugarolas J. Targeting renal cell carcinoma with a HIF-2 Antagonist. <i>Nature</i> 2016; 539:112-117.
14.	Li J, Alyamani M, Zhang A, Chang K-H, Berk M, Li Z, Zhu Z, Petro M, Magi-Galluzzi C, Taplin M-E, Garcia JA, Courtney K , Klein EA, Sharifi N. <i>eLife</i> 2016;5:e20183.
15.	Tumati V, Jackson WC, Abugharib AE, Raj G, Roehrborn C, Lotan Y, Courtney K , Bagrodia A, Gahan JC, Zumsteg ZS, Folkert MR, Laine AM, Hannan R, Spratt DE, Desai NB. Natural history of 'second' biochemical failure after salvage radiation therapy for prostate cancer: a multi-institution study. <i>BJU Int.</i> 2018 Mar;121(3):365-372. doi: 10.1111/bju.13926. Epub 2017 Jul 5.
16.	Courtney KD* , Infante JR, Lam ET, Figlin RA, Rini BI, Brugarolas J, Zojwalla NJ, Lowe AM, Wang K, Wallace EM, Josey JA, Choueiri TK. Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2 α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma. <i>J Clin Oncol.</i> 2018 Mar 20;36(9):867-874. doi: 10.1200/JCO.2017.74.2627. Epub 2017 Dec 19. PMID 29257710 *Corresponding author.
17.	Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, and Small EJ, et al., for the SPARTAN Investigators* Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. <i>N Engl J Med.</i> February 8, 2018. DOI: 10.1056/NEJMoa1715546.
18.	Mohamad O, Diaz de Leon A, Schroeder S, Leiker A, Christie A, Zhang-Velten E, Trivedi L, Khan S, Desai NB, Laine A, Albuquerque K, Iyengar P, Arriaga Y, Courtney K , Gerber D, Hammers H, Choy H, Timmerman R, Brugarolas J, Hannan R. Safety and Efficacy of Concurrent Immune Checkpoint Inhibitors and Hypofractionated Body Radiotherapy. <i>Oncoimmunology.</i> 2018 Mar 15;7(7):e1440168. doi: 10.1080/2162402X.2018.1440168. eCollection 2018. PMID: 29900043.
19.	Fets L, Driscoll PC, Grimm F, Jain A, Nunes PM, Gounis M, Doglioni G, Papageorgiou G, Ragan TJ, Campos S, dos Santos MS, MacRae JI, O'Reilly N, Wright AJ, Benes CH, Courtney K , House D, and Anastasiou D. Concentration-dependent inhibition of glutamine metabolism by methylalanyl-glycine mediated by monocarboxylate transporter 2. <i>Nature Chemical Biology.</i> PMID: 30297875 (2018).
20.	Kobayashi M, Chung J-S, Beg M, Arriaga Y, Verma U, Courtney K , Mansour JC, Haley B, Khan SA, Horiuchi Y, Ramani V, Harker D, Gopal P, Araghizadeh F, Cruz PD Jr. Blocking monocytic myeloid-derived suppressor cell function via anti-DC-HIL/GPNMB antibody restores the in vitro integrity of T-cells from cancer patients. <i>Clinical Cancer Research</i> PMID: 30049749 (2018).
21.	Courtney KD *+, Bezwada D*, Mashimo T, Pichumani K, Vemireddy V, Funk AM, Wimberly J, McNeil SS, Kapur P, Lotan Y, Margulis V, Cadeddu JA, DeBerardinis RJ, Malloy CR, Bachoo RM, Maher EA+. Isotope tracing of human clear cell renal cell carcinomas demonstrates suppressed glucose oxidation in vivo. <i>Cell Metabolism.</i> PMID: 30146487 (2018). *First author, + Corresponding author.
22.	Bowman I, Christie A, Bent A, Mickey B, Hammers H, Brugarolas J, Courtney K , Nedzi L, Hannan R, Timmerman R, Barnett S, Stojadinovic S, Whitworth T, Patel T, Le T, Arriaga Y, Wardak Z. Improved survival outcomes for kidney cancer patients with brain metastases. <i>Clinical Genitourinary Cancer.</i> 2018 Dec 5. pii: S1558-7673(18)30416-6. doi: 10.1016/j.clgc.2018.11.007. [Epub ahead of print]
23.	Zhang Y, Schoenhals J, Christie A, Mohamad O, Wang C, Bowman I, Singla N, Hammers

	H, Courtney K , Bagrodia A, Margulis V, Desai N, Garant A, Choy H, Brugarolas J, Timmerman R, Hannan R. Stereotactic Ablative Radiotherapy (SABR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer. 2019 Jul 29. pii: S0360-3016(19)33526-6. doi: 10.1016/j.ijrobp.2019.07.023. [Epub ahead of print]
--	---

Reviews, Chapters, Monographs and Editorials

1.	Wetterhahn KE, Stearns DM, Misra M, Giangrande PH, Phieffer LS, Kennedy LJ, and Courtney KD . The role of ascorbate in metabolism and genotoxicity of chromium (VI). In: Sarkar B, editor. Genetic Response to Metals. New York: Marcel Dekker, Inc.; 1995.
2.	Shaywitz AJ, Courtney KD , Patnaik A, and Cantley LC. PI3K enters beta-testing. Cell Metabolism 2008; 8: 179-181.
3.	Courtney KD and Choueiri TK. Optimizing Recent Advances in Metastatic Renal Cell Carcinoma. Current Oncology Reports 2009; 11:218-226.
4.	Courtney KD , Corcoran RB, and Engelman JA. The PI3K pathway as drug target in human cancer. Journal of Clinical Oncology 2010; 28:1075-83.
5.	Courtney KD , and Choueiri TK. Updates on novel therapies for metastatic renal cancer. Therapeutic Advances in Medical Oncology 2010; 2:209-219.
6.	Courtney KD , Cho DC, and Choueiri TK. Emerging and Novel Therapeutic Targets in Renal Cancer. In Emerging Cancer Therapeutics 2011, 2:145-156.
8.	Courtney KD and Taplin ME. The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer. Current Opinion in Oncology 2012; 24:272-277.
9.	Courtney KD and Cantley LC. PI3K. In PI3K. In Molecular Oncology: Causes of Cancer and Targets for Treatment. EP Gelmann, CL Sawyers, and FJ Rauscher III, Eds. Cambridge University Press, 2014.
10.	Courtney KD . Section: prostate cancer genetics. Video learning program. UTSW Medical Center: Hereditary Cancer Syndromes: From Identifying Patients At Risk To Navigating Patients to Management (EM1908A). Continuing medical education enduring material in video format. Ross T, Course Director. Available credit: 0.75 AMA. Course available 07/01/18 – 08/31/19. https://cme.utsouthwestern.edu/em1908a

Case Reports

1.	Memtsoudis SG, Lekowski RW, Jr., Rosenberger P, Khalpey Z, FitzGerald DJ, Claypoole V, Courtney KD , Landzberg MJ, Bunn HF, Shekar PS. Pulmonary thrombectomy in a patient with hemoglobin Nottingham. Perfusion 2007; 22: 299-301.
----	--

Proceedings of Meetings

1.	Laura-Maria Krabbe, Mary Elizabeth Westerman, Vitaly Margulis, Ganesh Raj, Arthur I. Sagalowsky, Kevin Dale Courtney, Yull Edwin Arriaga, Yair Lotan. Changing trends in utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer. 2014 ASCO Annual Meeting. J Clin Oncol 32, 2014 (suppl; abstr e15518)
2.	Raquibul Hannan, Dan Ishihara, Kristi Louder, Chul Ahn, Vitaly Margulis, Yull Edwin Arriaga, Kevin Dale Courtney, Robert D. Timmerman, James Brugarolas. Phase II trial of high-dose interleukin-2 (IL-2) and stereotactic Radiation therapy (SABR) for metastatic clear cell renal cell carcinoma (ccRCC): Interim analysis. 2016 ASCO Genitourinary Cancers Symposium. J

	Clin Oncol 34, 2016 (suppl 2S; abstr 532)
3.	Kevin Dale Courtney, Jeffrey R. Infante, Elaine Tat Lam, Robert A. Figlin, Brian I. Rini, James Brugarolas, Naseem J. Zojwalla, Keshi Wang, Eli Wallace, John A. Josey, Toni K. Choueiri. A phase I dose escalation trial of PT2385, a first-in-class oral HIF-2a inhibitor, in patients with advanced clear cell renal cell carcinoma. 2016 ASCO Annual Meeting. Oral Abstract Session. J Clin Oncol 34, 2016 (suppl; abstr 2506)
4.	Divya Bezwada, Elizabeth Maher, Ralph DeBerardinis, Kevin Courtney. Comparing Metabolic Labeling of Human Tumors at Different Anatomic Sites. Keystone Symposia on Molecular and Cellular Biology. Tumor Metabolism (A5). January 21—25, 2018, Snowbird Resort • Snowbird, Utah USA.
5.	Nima Sharifi, Jianneng Li, Mohammad Alyamani, Ao Zhang, Kai-Hsiung Chang, Mike Berk, Zhenfei Li, Ziqi Zhu, Marianne Petro, Mary-Ellen Taplin, Jorge A. Garcia, Kevin Dale Courtney, Eric A. Klein. Aberrant tumor metabolism to enable glucocorticoid receptor takeover in enzalutamide-resistant prostate cancer. 2017 ASCO Genitourinary Cancers Symposium. J Clin Oncol 35, 2017 (suppl 6S; abstract 157)
6.	Judy Sing-Zan Wang, Minal A. Barve, E. Gabriela Chiorean, Patricia LoRusso, Kevin Dale Courtney, Dan Qi, Arturo Olguin, John Bullington, Megan Sardone, Vanessa Dunn, Shay Shemesh, Janice Chen, Christopher Brooks, Todd Michael Bauer. Interim results from a phase 1 trial of SL-801, a novel XPO-1 inhibitor, in patients with advanced solid tumors. 2018 ASCO Annual Meeting. J Clin Oncol 36, 2018 (suppl; abstr 2560)

Non-peer reviewed scientific or medical publications/materials in print or other media

1.	Courtney K. (1999) Embryology. In: Yeh B, Paydarfar JA, Flynn M, Biswas SS, Bulsara KR, Liao L, Wu S, editors. <i>Crashing the Boards: A Friendly Study Guide for the USMLE Step 1</i> . 2 nd ed. Baltimore, MD: Lippincott Williams & Wilkins; 1999. pp. 97-111.
----	---